Mandate Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market

June 29, 2018

Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market. Trading in Calliditas Therapeutics’ shares on Nasdaq Stockholm commences today, 29 June 2018.

The price in the offering was set at SEK 45 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 1,593 million, assuming full exercise of the over-allotment option in the offering. Assuming full exercise of the over-allotment option, the value of the offering amounts to approximately SEK 747 million before transaction costs. 

Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy.
  
Vinge’s team primarily consists of Dain Hård Nevonen, Johan Larsson, Maria Schultzberg, Sofie Bjärtun, Sabina Kihlberg, Filip Öhrner, Victor Ericsson and William Kåge. 

Clarification of the interpretation of ”nearest suitable railway station”

Road transport performed by Samskip Sia in Sweden has been confirmed to be within the framework of a permitted combined transport through a decision of the Administrative court of Falun in Sweden. The central question in the case was how to interpret the term “nearest suitable railway station”
June 30, 2020

DAC 6 – EU Directive concerning reportable cross‑border tax arrangements

DAC 6 is a EU Directive which entails that advisers are subject to a duty to notify the relevant tax authorities concerning their client’s cross‑border arrangements. The purpose of the information disclosure obligation is to combat tax evasion, tax fraud and tax avoidance.
June 04, 2020

The importance of continuous focus on compliance procedures in disrupting times

A large number of corporations will most certainly be severely impacted by the effects of the Covid-19 pandemic. The new challenges will impact companies’ compliance risks, which are likely to be different and, to a certain extent, increased. It is crucial that - also in disrupting times - internal compliance procedures are maintained and that new risks are identified and mitigated.
May 28, 2020